Today: 19 April 2026
UOB share price slips as MAS turns slightly hawkish — what investors watch next
30 January 2026
2 mins read

UOB share price slips as MAS turns slightly hawkish — what investors watch next

Singapore, Jan 30, 2026, 14:51 SGT — Regular session

  • UOB shares dropped 0.6% on Friday, while Singapore bank stocks showed a mixed performance.
  • MAS left policy unchanged but lifted its inflation forecast for 2026, rattling some risk bets.
  • Attention shifts to UOB’s Feb. 24 earnings for clues on margins and credit costs.

United Overseas Bank Ltd (UOB) shares dipped 0.6% to S$38.41 on Friday, slipping 24 Singapore cents from Thursday’s finish. Trading remained uneven following a solid rally in local banks. The stock fluctuated between S$38.40 and S$38.65. Meanwhile, DBS dropped 0.8% and OCBC inched up 0.2%.

The pullback is significant since Singapore’s banks have been carrying much of the weight for local equities. Investors are now wrestling with how “higher for longer” inflation could impact earnings, trying not to get ahead of themselves on valuations.

This comes as the earnings season is about to heat up. UOB won’t report for several weeks yet, but investors are already focusing intently on guidance—particularly around loan quality and the direction of margins.

On Thursday, the Monetary Authority of Singapore held its exchange-rate policy steady but raised its 2026 core and headline inflation forecasts to 1.0%–2.0%, up from 0.5%–1.5%, citing upside risks to growth and inflation. OCBC economist Selena Ling described the central bank’s tone as “a tad more hawkish and less dovish,” while Maybank’s Chua Hak Bin noted “simmering inflation pressures emerging.” Reuters

Brokers pushed prices higher, only to pull them back again. According to The Business Times, UOB’s consensus target price climbed to S$37.26, even as the stock lingered above that mark after hitting a record S$39.50 last week. Macquarie’s Jayden Vantarakis labeled UOB a “catch-up play,” while JPMorgan downgraded its rating to “underweight.”

Traders see it plainly: the rally already baked in plenty of good news, so minor changes in the macro outlook can spark profit-taking. UOB’s Friday move felt more like repositioning than a reaction to new company developments.

Feb. 24 is the next key date. UOB announced in an exchange filing that it will publish its full-year 2025 financial results ahead of the market open that day.

Investors are keenly eyeing any shift in the bank’s forecast for net interest margin — the difference between earnings on loans and expenses on deposits — along with updates on credit costs and fee income. Signals about dividends will also draw attention, especially following the stock’s strong rally this month.

UOB has flagged a potential dip in margins as the rate cycle shifts. Back in November, the bank forecast its full-year 2026 net interest margin to land between 1.75% and 1.80%, which is lower than its 2025 estimate. It also projected total credit costs to range from 25 to 30 basis points.

There is a downside risk. Should inflation remain stubborn and policy tighten further later this year, funding costs might outpace asset yields. A shaky global economy could also trigger a swift rise in credit provisions, particularly for a regionally-focused lender like UOB.

Investors are now eyeing UOB’s report due Feb. 24, with keen interest in what management reveals about margins and loan stress as 2026 approaches.

Stock Market Today

  • How Defensive Stocks Could Boost Your 401(k) This Summer
    April 18, 2026, 10:58 PM EDT. Seasonal stock market trends suggest selling in May, but experts caution against it in 2026. Instead, financial analysts Mark Hulbert and Sam Stovall recommend rotating investments into defensive stocks during the summer months. These stocks, found in sectors like healthcare and consumer staples, are less sensitive to economic swings and provide stable returns. Hulbert advises using ETFs such as Consumer Staples Select Sector SPDR (XLP) and Health Care Select Sector SPDR (XLV) for this strategy. These ETFs offer low fees and exposure to essential goods and services companies, offering potential portfolio stability during typical market volatility in May to October. This approach could make a meaningful difference to your 401(k) performance by balancing growth and risk through seasonal shifts.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Bellevue Gold share price slides 5% as gold tumbles from record highs — what to watch next week
Previous Story

Bellevue Gold share price slides 5% as gold tumbles from record highs — what to watch next week

Keppel share price drops as Singapore investors weigh SAF project ahead of Feb 5 earnings
Next Story

Keppel share price drops as Singapore investors weigh SAF project ahead of Feb 5 earnings

Go toTop